AbbVie Inc (ABBV)vsLivaNova PLC (LIVN)
ABBV
AbbVie Inc
$203.89
+3.64%
HEALTHCARE · Cap: $360.63B
LIVN
LivaNova PLC
$58.92
-3.87%
HEALTHCARE · Cap: $3.51B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 4306% more annual revenue ($61.16B vs $1.39B). ABBV leads profitability with a 6.9% profit margin vs -17.5%. ABBV appears more attractively valued with a PEG of 0.48. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
LIVN
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$203.89
$40.47 premium
Margin of Safety
+34.9%
Fair Value
$102.04
Current Price
$58.92
$43.12 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Weak financial health signals
ROE of -19.2% — below average capital efficiency
Earnings declined 45.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : LIVN
The strongest argument for LIVN centers on PEG Ratio, Price/Book. Revenue growth of 12.1% demonstrates continued momentum. PEG of 0.74 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : LIVN
The primary concerns for LIVN are Piotroski F-Score, Return on Equity, EPS Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while LIVN is a turnaround play — different risk/reward profiles.
LIVN carries more volatility with a beta of 0.97 — expect wider price swings.
LIVN is growing revenue faster at 12.1% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 48/100). LIVN offers better value entry with a 34.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
LivaNova PLC
HEALTHCARE · MEDICAL DEVICES · USA
LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?